Lexibulin

Drug Profile

Lexibulin

Alternative Names: CYT 997

Latest Information Update: 25 Feb 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytopia Limited
  • Developer YM BioSciences Australia
  • Class Antineoplastics; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Glioblastoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 08 Feb 2013 YM BioSciences has been acquired by Gilead Sciences
  • 07 Nov 2010 Discontinued - Phase-II for Multiple myeloma in Australia (IV)
  • 01 Feb 2010 Cytopia Limited has been acquired by YM BioSciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top